Literature DB >> 34077540

Neoplastic and immune single-cell transcriptomics define subgroup-specific intra-tumoral heterogeneity of childhood medulloblastoma.

Kent A Riemondy1, Sujatha Venkataraman2,3, Nicholas Willard4, Anandani Nellan2,3, Bridget Sanford2, Andrea M Griesinger2,3, Vladimir Amani2,3, Siddhartha Mitra2,3, Todd C Hankinson5,3, Michael H Handler5,3, Martin Sill6,7, Jennifer Ocasio8, Seth J Weir8, Daniel S Malawsky8, Timothy R Gershon8, Alexandra Garancher9, Robert J Wechsler-Reya9, Jay R Hesselberth1, Nicholas K Foreman2,5,3, Andrew M Donson2,3, Rajeev Vibhakar2,3.   

Abstract

BACKGROUND: Medulloblastoma (MB) is a heterogeneous disease in which neoplastic cells and associated immune cells contribute to disease progression. We aimed to determine the influence of neoplastic and immune cell diversity on MB biology in patient samples and animal models.
METHODS: To better characterize cellular heterogeneity in MB we used single-cell RNA sequencing, immunohistochemistry, and deconvolution of transcriptomic data to profile neoplastic and immune populations in patient samples and animal models across childhood MB subgroups.
RESULTS: Neoplastic cells cluster primarily according to individual sample of origin which is influenced by chromosomal copy number variance. Harmony alignment reveals novel MB subgroup/subtype-associated subpopulations that recapitulate neurodevelopmental processes, including photoreceptor and glutamatergic neuron-like cells in molecular subgroups GP3 and GP4, and a specific nodule-associated neuronally differentiated subpopulation in the sonic hedgehog subgroup. We definitively chart the spectrum of MB immune cell infiltrates, which include subpopulations that recapitulate developmentally related neuron-pruning and antigen-presenting myeloid cells. MB cellular diversity matching human samples is mirrored in subgroup-specific mouse models of MB.
CONCLUSIONS: These findings provide a clearer understanding of the diverse neoplastic and immune cell subpopulations that constitute the MB microenvironment.
© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  immune; medulloblastoma; neoplastic; scRNA-seq; subpopulation

Mesh:

Substances:

Year:  2022        PMID: 34077540      PMCID: PMC8804892          DOI: 10.1093/neuonc/noab135

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   13.029


  38 in total

Review 1.  Microglia Function in Central Nervous System Development and Plasticity.

Authors:  Dorothy P Schafer; Beth Stevens
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-07-17       Impact factor: 10.005

2.  Wnt/β-catenin signaling inhibits the Shh pathway and impairs tumor growth in Shh-dependent medulloblastoma.

Authors:  Julia Pöschl; Martin Bartels; Jasmin Ohli; Edoardo Bianchi; Konstantin Kuteykin-Teplyakov; Daniel Grammel; Julia Ahlfeld; Ulrich Schüller
Journal:  Acta Neuropathol       Date:  2014-02-15       Impact factor: 17.088

Review 3.  Microglia and macrophages in brain homeostasis and disease.

Authors:  Qingyun Li; Ben A Barres
Journal:  Nat Rev Immunol       Date:  2017-11-20       Impact factor: 53.106

4.  Characterization of distinct immunophenotypes across pediatric brain tumor types.

Authors:  Andrea M Griesinger; Diane K Birks; Andrew M Donson; Vladimir Amani; Lindsey M Hoffman; Allen Waziri; Michael Wang; Michael H Handler; Nicholas K Foreman
Journal:  J Immunol       Date:  2013-09-27       Impact factor: 5.422

5.  Medulloblastoma comprises four distinct molecular variants.

Authors:  Paul A Northcott; Andrey Korshunov; Hendrik Witt; Thomas Hielscher; Charles G Eberhart; Stephen Mack; Eric Bouffet; Steven C Clifford; Cynthia E Hawkins; Pim French; James T Rutka; Stefan Pfister; Michael D Taylor
Journal:  J Clin Oncol       Date:  2010-09-07       Impact factor: 44.544

6.  GSK-3 modulates SHH-driven proliferation in postnatal cerebellar neurogenesis and medulloblastoma.

Authors:  Jennifer K Ocasio; Rolf Dale P Bates; Carolyn D Rapp; Timothy R Gershon
Journal:  Development       Date:  2019-10-10       Impact factor: 6.868

7.  HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma.

Authors:  Yanxin Pei; Kun-Wei Liu; Jun Wang; Alexandra Garancher; Ran Tao; Lourdes A Esparza; Donna L Maier; Yoko T Udaka; Najiba Murad; Sorana Morrissy; Huriye Seker-Cin; Sebastian Brabetz; Lin Qi; Mari Kogiso; Simone Schubert; James M Olson; Yoon-Jae Cho; Xiao-Nan Li; John R Crawford; Michael L Levy; Marcel Kool; Stefan M Pfister; Michael D Taylor; Robert J Wechsler-Reya
Journal:  Cancer Cell       Date:  2016-03-14       Impact factor: 31.743

8.  NeuroD1 Dictates Tumor Cell Differentiation in Medulloblastoma.

Authors:  Yan Cheng; Shengyou Liao; Gang Xu; Jian Hu; Duancheng Guo; Fang Du; Alejandra Contreras; Kathy Q Cai; Suraj Peri; Yuan Wang; David C Corney; Anne Marie Noronha; Lianne Q Chau; Ginger Zhou; David L Wiest; Alfonso Bellacosa; Robert J Wechsler-Reya; Yi Zhao; Zeng-Jie Yang
Journal:  Cell Rep       Date:  2020-06-23       Impact factor: 9.423

9.  Childhood cerebellar tumours mirror conserved fetal transcriptional programs.

Authors:  Maria C Vladoiu; Ibrahim El-Hamamy; Laura K Donovan; Nada Jabado; Lincoln Stein; Michael D Taylor; Hamza Farooq; Borja L Holgado; Yogi Sundaravadanam; Vijay Ramaswamy; Liam D Hendrikse; Sachin Kumar; Stephen C Mack; John J Y Lee; Vernon Fong; Kyle Juraschka; David Przelicki; Antony Michealraj; Patryk Skowron; Betty Luu; Hiromichi Suzuki; A Sorana Morrissy; Florence M G Cavalli; Livia Garzia; Craig Daniels; Xiaochong Wu; Maleeha A Qazi; Sheila K Singh; Jennifer A Chan; Marco A Marra; David Malkin; Peter Dirks; Lawrence Heisler; Trevor Pugh; Karen Ng; Faiyaz Notta; Eric M Thompson; Claudia L Kleinman; Alexandra L Joyner
Journal:  Nature       Date:  2019-05-01       Impact factor: 49.962

10.  The whole-genome landscape of medulloblastoma subtypes.

Authors:  Paul A Northcott; Ivo Buchhalter; A Sorana Morrissy; Volker Hovestadt; Joachim Weischenfeldt; Tobias Ehrenberger; Susanne Gröbner; Maia Segura-Wang; Thomas Zichner; Vasilisa A Rudneva; Hans-Jörg Warnatz; Nikos Sidiropoulos; Aaron H Phillips; Steven Schumacher; Kortine Kleinheinz; Sebastian M Waszak; Serap Erkek; David T W Jones; Barbara C Worst; Marcel Kool; Marc Zapatka; Natalie Jäger; Lukas Chavez; Barbara Hutter; Matthias Bieg; Nagarajan Paramasivam; Michael Heinold; Zuguang Gu; Naveed Ishaque; Christina Jäger-Schmidt; Charles D Imbusch; Alke Jugold; Daniel Hübschmann; Thomas Risch; Vyacheslav Amstislavskiy; Francisco German Rodriguez Gonzalez; Ursula D Weber; Stephan Wolf; Giles W Robinson; Xin Zhou; Gang Wu; David Finkelstein; Yanling Liu; Florence M G Cavalli; Betty Luu; Vijay Ramaswamy; Xiaochong Wu; Jan Koster; Marina Ryzhova; Yoon-Jae Cho; Scott L Pomeroy; Christel Herold-Mende; Martin Schuhmann; Martin Ebinger; Linda M Liau; Jaume Mora; Roger E McLendon; Nada Jabado; Toshihiro Kumabe; Eric Chuah; Yussanne Ma; Richard A Moore; Andrew J Mungall; Karen L Mungall; Nina Thiessen; Kane Tse; Tina Wong; Steven J M Jones; Olaf Witt; Till Milde; Andreas Von Deimling; David Capper; Andrey Korshunov; Marie-Laure Yaspo; Richard Kriwacki; Amar Gajjar; Jinghui Zhang; Rameen Beroukhim; Ernest Fraenkel; Jan O Korbel; Benedikt Brors; Matthias Schlesner; Roland Eils; Marco A Marra; Stefan M Pfister; Michael D Taylor; Peter Lichter
Journal:  Nature       Date:  2017-07-19       Impact factor: 49.962

View more
  8 in total

1.  Faraway, so close: Intratumoral heterogeneity of medulloblastoma subgroups.

Authors:  Livia Garzia
Journal:  Neuro Oncol       Date:  2022-02-01       Impact factor: 12.300

2.  Gene expression profiling of Group 3 medulloblastomas defines a clinically tractable stratification based on KIRREL2 expression.

Authors:  Andrey Korshunov; Konstantin Okonechnikov; Damian Stichel; Daniel Schrimpf; Alberto Delaidelli; Svenja Tonn; Martin Mynarek; Philipp Sievers; Felix Sahm; David T W Jones; Andreas von Deimling; Stefan M Pfister; Marcel Kool
Journal:  Acta Neuropathol       Date:  2022-06-30       Impact factor: 15.887

3.  Intratumoral heterogeneity of MYC drives medulloblastoma metastasis and angiogenesis.

Authors:  Nan Qin; Eunice Paisana; Maike Langini; Daniel Picard; Bastian Malzkorn; Carlos Custódia; Rita Cascão; Frauke-Dorothee Meyer; Lena Blümel; Sarah Göbbels; Kübra Taban; Jasmin Bartl; Nicole Bechmann; Catleen Conrad; Jan Gravemeyer; Jürgen C Becker; Anja Stefanski; Stéphanie Puget; João T Barata; Kai Stühler; Ute Fischer; Jörg Felsberg; Olivier Ayrault; Guido Reifenberger; Arndt Borkhardt; Graeme Eisenhofer; Claudia C Faria; Marc Remke
Journal:  Neuro Oncol       Date:  2022-09-01       Impact factor: 13.029

4.  Dissecting super-enhancer driven transcriptional dependencies reveals novel therapeutic strategies and targets for group 3 subtype medulloblastoma.

Authors:  Meng Li; Yujie Han; Chaochen Wang; Wenfeng Kang; Wenyan Jiang; Lei Zhang; Yujie Tang
Journal:  J Exp Clin Cancer Res       Date:  2022-10-22

Review 5.  Coming in from the cold: overcoming the hostile immune microenvironment of medulloblastoma.

Authors:  Tanja Eisemann; Robert J Wechsler-Reya
Journal:  Genes Dev       Date:  2022-05-01       Impact factor: 12.890

6.  Integrated computational analyses reveal novel insights into the stromal microenvironment of SHH-subtype medulloblastoma.

Authors:  Alexander P Landry; Nardin Samuel; Julian Spears; Zsolt Zador
Journal:  Sci Rep       Date:  2021-10-19       Impact factor: 4.379

Review 7.  The Current Landscape of Targeted Clinical Trials in Non-WNT/Non-SHH Medulloblastoma.

Authors:  David R Ghasemi; Gudrun Fleischhack; Till Milde; Kristian W Pajtler
Journal:  Cancers (Basel)       Date:  2022-01-28       Impact factor: 6.639

8.  Conventional Therapies Deplete Brain-Infiltrating Adaptive Immune Cells in a Mouse Model of Group 3 Medulloblastoma Implicating Myeloid Cells as Favorable Immunotherapy Targets.

Authors:  Zahra Abbas; Courtney George; Mathew Ancliffe; Meegan Howlett; Anya C Jones; Mani Kuchibhotla; Robert J Wechsler-Reya; Nicholas G Gottardo; Raelene Endersby
Journal:  Front Immunol       Date:  2022-03-03       Impact factor: 8.786

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.